Literature DB >> 1704405

Tumor markers in patients with chronic renal failure.

X Filella1, A Cases, R Molina, J Jo, J L Bedini, L Revert, A M Ballesta.   

Abstract

In order to evaluate the specificity of tumor markers in chronic renal failure, we have determined serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA 19.9), carbohydrate antigen 50 (CA 50), alphafetoprotein (AFP), neuron-specific enolase (NSE), prostatic acid phosphatase (PAP), prostatic specific antigen (PSA), squamous cell carcinoma antigen (SCC), carbohydrate antigen 15.3 (CA 15.3) and carbohydrate antigen 125 (CA 125) in 30 patients with chronic renal failure and in 36 hemodialyzed patients without clinical evidence of neoplasia. CEA, CA 50, NSE and SCC frequently show increased serum levels, suggesting a renal metabolism, while others remain, generally, within the normal levels.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1704405

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN： 0393-6155            Impact factor:   2.659


  9 in total

Review 1.  [Diagnostics and treatment of prostate cancer after kidney transplantation].

Authors:  A Wicht; A Hamza; H Loertzer; M Dietl; H Heynemann; P Fornara
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

2.  Predictive value of neuron-specific enolase for prognosis in patients with moderate or severe traumatic brain injury: a systematic review and meta-analysis.

Authors:  Eric Mercier; Amélie Boutin; Michèle Shemilt; François Lauzier; Ryan Zarychanski; Dean A Fergusson; Lynne Moore; Lauralyn A McIntyre; Patrick Archambault; France Légaré; François Rousseau; François Lamontagne; Linda Nadeau; Alexis F Turgeon
Journal:  CMAJ Open       Date:  2016-07-22

3.  Serum tumour markers in renal failure.

Authors:  N Arik; B Adam; T Akpolat; K Haşil; S Tabak
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

4.  Effect of renal function and hemodialysis on the serum tumor markers in patients with chronic kidney disease.

Authors:  Xiaofang Yu; Xialian Xu; Zhibin Ye
Journal:  Front Med China       Date:  2007-07

5.  Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease.

Authors:  Frank Tacke; Nicolas Kanig; Abdelaziz En-Nia; Thilo Kaehne; Christiane S Eberhardt; Victoria Shpacovitch; Christian Trautwein; Peter R Mertens
Journal:  BMC Cancer       Date:  2011-05-20       Impact factor: 4.430

Review 6.  Gamma-enolase: a well-known tumour marker, with a less-known role in cancer.

Authors:  Tjasa Vizin; Janko Kos
Journal:  Radiol Oncol       Date:  2015-08-21       Impact factor: 2.991

7.  How to define a cut-off value of tumour markers in haemodialysis patients?

Authors:  Lucile Mercadal; Sylvie Cormont; Sophie Tezenas-du-Montcel; Sabria Hacini; Marcia Venditto; Gilbert Deray
Journal:  NDT Plus       Date:  2009-04

Review 8.  Tumour markers and kidney function: a systematic review.

Authors:  Giuseppe Coppolino; Davide Bolignano; Laura Rivoli; Giuseppe Mazza; Piera Presta; Giorgio Fuiano
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

9.  Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.

Authors:  Gustav Mikkelsen; Arne Åsberg; Maria E Hultström; Knut Aasarød; Gunhild G Hov
Journal:  Int J Biol Markers       Date:  2017-10-31       Impact factor: 2.659
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.